Recurrent Childhood Ependymoma Clinical Trial
Official title:
Phase II Study of Bevacizumab Plus Irinotecan (Camptosarâ„¢) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas
This phase II trial is studying how well giving bevacizumab together with irinotecan works in treating young patients with recurrent, progressive, or refractory glioma, medulloblastoma, ependymoma, or low grade glioma. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the growth of glioma by blocking blood flow to the tumor. Drugs used in chemotherapy, such as irinotecan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with irinotecan may kill more tumor cells.
PRIMARY OBJECTIVES:
I. Estimate the rates of objective response observed prior to disease progression during the
first four courses of treatment with bevacizumab and irinotecan hydrochloride in pediatric
patients with recurrent, progressive, or refractory malignant glioma (Stratum A [closed to
accrual as of 4/21/2009]) or recurrent/progressive/refractory intrinsic brain stem glioma
(Stratum B [closed to accrual as of 4/21/2009]).
II. Estimate the rates of objective response observed prior to disease progression during the
first four courses of treatment with bevacizumab and irinotecan hydrochloride in patients
with recurrent or progressive medulloblastoma (Stratum C [closed to accrual as of
10/27/2009]) or recurrent or progressive ependymoma (Stratum D [closed to accrual as of
7/29/2010]).
III. Estimate the sustained disease stabilization rate associated with bevacizumab and
irinotecan in patients with recurrent or progressive low grade glioma (Stratum E [closed to
accrual as of 7/29/2010]).
SECONDARY OBJECTIVES:
I. Estimate the rate of treatment-related toxicity of this regimen in these patients.
II. Estimate the cumulative incidence of sustained objective responses as a function of this
regimen in these patients.
III. Estimate the distributions of survival and event-free survival of these patients.
IV. Correlate functional changes in tumor with progression-free survival and response using
MR perfusion/diffusion imaging and fludeoxyglucose F 18 positron emission tomography.
OUTLINE: This is a multicenter study. Patients are stratified according to tumor type
(high-grade glioma [closed to accrual as of 4/21/2009] vs intrinsic brain stem tumor [closed
to accrual as of 4/21/2009] vs medulloblastoma [closed to accrual as of 10/27/2010] vs
ependymoma [closed to accrual as of 7/29/2010] vs low grade glioma [closed to accrual as of
7/29/2010]).
Patients receive bevacizumab IV over 30-90 minutes on days 1 and 15 and irinotecan
hydrochloride IV over 90 minutes on day 16 or 17 for course 1. Patients receive bevacizumab
and irinotecan hydrochloride on days 1 and 15 for all subsequent courses. Treatment repeats
every 4 weeks for up to 24 courses in the absence of disease progression or unacceptable
toxicity.
Patients undergo MRIs of the brain, magnetic resonance perfusion/diffusion, and
fludeoxyglucose F 18 positron emission tomography at baseline and periodically during
treatment.
After completion of study treatment, patients are followed for 30 days and then every 3
months for up to 2 years.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Withdrawn |
NCT02194452 -
Efficacy of 68Ga-DOTATOC Positron Emission Tomography (PET) CT in Children and Young Adults With Brain Tumors
|
N/A | |
Completed |
NCT00053963 -
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia
|
Phase 1 | |
Active, not recruiting |
NCT03233204 -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Completed |
NCT00091182 -
Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous Treatment
|
Phase 2 | |
Completed |
NCT00095940 -
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT00052780 -
Temozolomide and O6-Benzylguanine in Treating Children With Recurrent Brain Tumors
|
Phase 1 | |
Completed |
NCT00004078 -
Irinotecan in Treating Children With Refractory Solid Tumors
|
Phase 2 | |
Completed |
NCT00100880 -
Lenalidomide in Treating Young Patients With Recurrent, Progressive, or Refractory CNS Tumors
|
Phase 1 | |
Recruiting |
NCT02359565 -
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
|
Phase 1 | |
Terminated |
NCT01088763 -
Gamma-Secretase Inhibitor RO4929097 in Treating Young Patients With Relapsed or Refractory Solid Tumors, CNS Tumors, Lymphoma, or T-Cell Leukemia
|
Phase 1 | |
Completed |
NCT00326664 -
AZD2171 in Treating Young Patients With Recurrent, Progressive, or Refractory Primary CNS Tumors
|
Phase 1 | |
Completed |
NCT00101270 -
Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas
|
Phase 1 | |
Active, not recruiting |
NCT03210714 -
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Completed |
NCT00363272 -
Ispinesib in Treating Young Patients With Relapsed or Refractory Solid Tumors or Lymphoma
|
Phase 1 | |
Completed |
NCT00946335 -
ABT-888 and Temozolomide in Treating Young Patients With Recurrent or Refractory CNS Tumors
|
Phase 1 | |
Completed |
NCT00063973 -
Cilengitide in Treating Children With Refractory Primary Brain Tumors
|
Phase 1 | |
Completed |
NCT01462695 -
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
|
Phase 2 | |
Completed |
NCT03387020 -
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
|
Phase 1 | |
Active, not recruiting |
NCT00638898 -
Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor
|
Phase 1 | |
Recruiting |
NCT05857969 -
Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling
|